X4 Pharmaceuticals (XFOR) Preferred Stock Liabilities (2017 - 2021)

X4 Pharmaceuticals has reported Preferred Stock Liabilities for 3 years, with the latest figure at $1.9 million in Q2 2021.

• For the quarter ending Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2021 stood at $1.9 million (changed N/A YoY), and the FY2018 full-year result was $4.9 million, down 91.88% from the prior year.
• Preferred Stock Liabilities for Q2 2021 stood at $1.9 million, roughly flat from $1.9 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $64.7 million in Q3 2018, with the low at $1.9 million in Q1 2021.
• Historically, Preferred Stock Liabilities has averaged $36.4 million across 3 years, with a median of $60.4 million in 2018.
• The largest YoY upside for Preferred Stock Liabilities was 91.88% in 2018 against a maximum downside of 91.88% in 2018.
• X4 Pharmaceuticals' Preferred Stock Liabilities stood at $60.9 million in 2017, then tumbled by 91.88% to $4.9 million in 2018, then slumped by 62.1% to $1.9 million in 2021.
• The last three Preferred Stock Liabilities figures came in at $1.9 million (Q2 2021), $1.9 million (Q1 2021), and $4.9 million (Q4 2018), per Business Quant data.